A (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione CEP of the European Pharmacopoeia monograph is often referred to as a (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione Certificate of Suitability (COS). The purpose of a (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione to their clients by showing that a (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione CEP has been issued for it. The manufacturer submits a (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione CEP (COS) as part of the market authorization procedure, and it takes on the role of a (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione CEP holder for the record. Additionally, the data presented in the (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione DMF.
A (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0?,?.0?,??.0??,??.0??,??]nonadecane-15,2'-oxolan]-5-ene-5',7-dione suppliers with CEP (COS) on PharmaCompass.